Xuan Wang

Mulberrofuran A (MFA), a natural product originally isolated from the root bark of Morus alba L. (Sang-Bai-Pi), is a structurally distinctive mulberry-derived 2-arylbenzofuran bearing a prenyl-related side chain. Although MFA has attracted attention because of its phytochemical uniqueness and reported biological relevance, the available evidence specific to MFA remains limited and fragmented. In addition, pharmacological interpretations are often complicated by the frequent use of indirect evidence derived from structurally related mulberrofuran analogues, other arylbenzofurans, or complex Morus extracts. This review critically summarizes current knowledge on the chemistry, occurrence, and biological relevance of MFA, while explicitly distinguishing direct MFA-specific evidence from indirect and contextual evidence. Available studies suggest that MFA may be associated with antimicrobial activity and modulation of arachidonic acid-related inflammatory pathways, whereas its putative roles in metabolic regulation, cardiovascular protection, antiviral activity, antioxidant effects, and anticancer relevance are currently supported mainly by structurally related compounds or broader mulberry literature rather than robust MFA-specific validation. We further discuss the limitations of the current evidence base, including methodological heterogeneity, incomplete statistical reporting, the lack of pharmacokinetic and toxicity data, and the absence of clinical validation. Rather than establishing MFA as a confirmed therapeutic agent, the available literature supports its consideration as an emerging natural product candidate that warrants rigorous chemical, pharmacological, and translational investigation.

Electroacupuncture (EA) can effectively relieve hyperglycemia and gastric emptying disorders in diabetic gastroparesis (DGP). However, the effect of EA on type 2 diabetes mellitus (T2DM) gastroparesis and its mechanism in the enteric nervous system (ENS) are rarely studied. We investigated the therapeutic effect of EA at ST36 and its effect on the main inhibitory and excitatory neurotransmitters in the ENS in DGP rats. Male Sprague-Dawley (SD) rats were fed a high-fat diet for 2 weeks and injected with streptozotocin (STZ) at 35 mg/kg to induce T2DM. T2DM rats were divided into the diabetic mellitus (DM) group and the EA group. The control (CON) group comprised normal rats without any intervention. EA treatment was started 6 weeks after the induction of DM and continued for 5 weeks. The body weight and food intake of the rats were recorded every week. Blood glucose, insulin, glucose tolerance, gastric emptying, and antral motility were measured after treatment. The expression of protein gene product 9.5 (PGP9.5), neuronal nitric oxide synthase (nNOS), and choline acetyltransferase (ChAT) in gastric antrum were quantified by western blotting and quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). The T2DM gastroparesis model was successfully established. EA treatment reduced the body weight, food intake, and blood glucose; improved glucose intolerance and insulin resistance; increased the gastric emptying rate, the mean antral pressure, and the amplitude of antral motility; and decreased the frequency of antral motility compared with those in the DM group. EA treatment increased the expression level of nNOS, ChAT, and PGP9.5 proteins, and nNOS and ChAT mRNA. The results suggested that EA at ST36 could ameliorate DGP, partly restore the damage to general neurons, and increase nNOS and ChAT in the gastric antrum. EA improved DGP partly via reducing the loss of inhibitory and excitatory neurotransmitters in the ENS.